li001

Intraoperative Cisplatin Patch PRV211 Meets Safety Goal in Oral Cancer Trial

Treatment /

Privo Technologies announced that its intraoperative cisplatin patch, PRV211, met the primary safety endpoint in Arm 2 of the Phase 2/3 CLN-004 trial for patients with invasive oral cavity cancer. In the earlier phase 1/2 group of eight patients, no treatment-related serious adverse events, systemic toxicities, or dose-limiting toxicities were observed, and wound healing was […]

Intraoperative Cisplatin Patch PRV211 Meets Safety Goal in Oral Cancer Trial Read More »

AI Boosts Early Lung Cancer Detection and Speeds Up CT Scan Reading

Diagnostics /

New research shows that adding a deep-learning AI tool to chest CT interpretation can significantly improve radiologists’ ability to detect early-stage lung cancer while maintaining accuracy. The study found that AI assistance increased detection sensitivity by 24.3% without significantly increasing false positives. It also made readings faster, reducing the average scan interpretation time by about

AI Boosts Early Lung Cancer Detection and Speeds Up CT Scan Reading Read More »

Combination Therapy Shows Strong Survival Benefit in Advanced Pancreatic Cancer

Treatment /

Interim results from a Phase 2a trial testing a combination of atebimetinib with modified gemcitabine/nabpaclitaxel (mGnP) have shown promising survival outcomes in patients with advanced pancreatic cancer. The study reported a 64 % overall survival rate at 12 months, a significant improvement over historical benchmarks achieved with standard chemotherapy alone. This combination therapy pairs traditional chemotherapy with atebimetinib,

Combination Therapy Shows Strong Survival Benefit in Advanced Pancreatic Cancer Read More »

Four-Marker Blood Test Brings New Hope for Early Detection of Pancreatic Cancer

Diagnostics /

Researchers have developed a new blood test that could greatly improve early detection of pancreatic cancer, a disease that is often diagnosed too late to treat effectively. Scientists combined four protein markers—CA19-9, THBS2, and two newly identified markers, ANPEP and PIGR—into a single test. Using all four markers together significantly increased accuracy. The test correctly

Four-Marker Blood Test Brings New Hope for Early Detection of Pancreatic Cancer Read More »

New Strategies Aim to Break Radiation Resistance in Pancreatic Cancer

Treatment /

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a poor survival rate, and most patients are not eligible for surgery. Radiation therapy has limited benefit because PDAC tumors are naturally resistant to radiation, using strategies such as low oxygen levels, strong DNA repair systems, and altered cell cycles to survive. To improve radiation effectiveness,

New Strategies Aim to Break Radiation Resistance in Pancreatic Cancer Read More »

AI and Molecular Biomarkers Redefine the Future of Lung Cancer Detection and Treatment

Diagnostics /

Lung cancer is still the leading cause of cancer-related death worldwide, largely due to smoking and environmental exposure. It mainly includes non-small cell lung cancer, which makes up most cases and has a low long-term survival rate, and small cell lung cancer, which is less common but more aggressive. Current diagnosis relies heavily on CT

AI and Molecular Biomarkers Redefine the Future of Lung Cancer Detection and Treatment Read More »

Scientists Unmask Pancreatic Cancer’s “Sugar-Coated” Defense, Opening New Path for Immunotherapy

Research Advances /

Researchers at Northwestern Medicine have discovered why pancreatic cancer often resists immunotherapy: the tumor hides behind a “sugar coating” that tells the immune system not to attack. The study, published in Cancer Research in January 2026, also describes a new antibody designed to strip away this disguise. Normally, healthy cells use a sugar called sialic acid

Scientists Unmask Pancreatic Cancer’s “Sugar-Coated” Defense, Opening New Path for Immunotherapy Read More »

Triple-Drug Therapy Erases Pancreatic Tumors in Mice, Raising Hope for Future Treatment

preclinical trails /

Researchers have developed a new three-drug treatment that completely eliminated pancreatic tumors in mice and stopped them from coming back. This is a major advance for pancreatic cancer, a disease with a five-year survival rate of about 13%. The therapy works by blocking three critical pathways that pancreatic tumors use to survive and grow. It

Triple-Drug Therapy Erases Pancreatic Tumors in Mice, Raising Hope for Future Treatment Read More »

FDA Approves Rybrevant Faspro Subcutaneous Injection for Faster Lung Cancer Treatment

Drug Approvals /

The FDA has approved Rybrevant Faspro (amivantamab with hyaluronidase) as a subcutaneous injection for adults with EGFR-mutated non-small cell lung cancer, covering all previous intravenous indications. The subcutaneous version works as well as the IV form, with similar effectiveness and overall survival, but can be given in about 5 minutes instead of 2–5 hours. It also greatly

FDA Approves Rybrevant Faspro Subcutaneous Injection for Faster Lung Cancer Treatment Read More »

FDA Approves Darzalex Faspro Combo for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

Diagnostics /

The FDA has approved Darzalex Faspro (daratumumab with hyaluronidase) combined with bortezomib, lenalidomide, and dexamethasone (VRd) for adults newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The approval is based on a study of 395 patients showing that adding Darzalex Faspro to VRd improved outcomes: 52.3% of patients achieved MRD negativity versus

FDA Approves Darzalex Faspro Combo for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant Read More »